Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Past debacles in the glucokinase class of compounds notwithstanding, India's leading research firm Advinus Therapeutics has announced that it has discovered a novel molecule - coded GKM-001 - for the treatment of type 2 diabetes
You may also be interested in...
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 2 of 2)
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 2 of 2)
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News
Known for his thought-provoking views on transforming Indian pharmaceutical research, Barbhaiya says multinational companies should shed conventional methods when teaming up with Indian companies for true innovation to thrive.